



Final Appraisal Recommendation
Advice No: 0620 – July 2020

Hydroxycarbamide (Xromi®) 100 mg/ml oral solution

Submission by Nova Laboratories Limited

Recommendation of AWMSG

Hydroxycarbamide (Xromi®) is recommended as an option for restricted use within NHS Wales.

Hydroxycarbamide (Xromi®) is licensed for the prevention of vaso-occlusive complications of sickle cell disease in patients over two years of age.

Hydroxycarbamide (Xromi®) is restricted for use for patients over two years of age who are unable to swallow capsules.

Hydroxycarbamide (Xromi®) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note:

- AWMSG considered hydroxycarbamide (Xromi®) as an orphan-equivalent medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4264), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0620:
Hydroxycarbamide (Xromi®) 100 mg/ml oral solution. July 2020.

